Advanced

Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease

Stålenheim, G; Wegener, T; Grettve, L; Lundback, B; Melander, B; Osterman, K; Piitulainen, Eeva LU and Zetterstrom, O (1994) In Respiration 61(6). p.305-309
Abstract
Formoterol, a new beta 2-agonist, and salbutamol were given as aerosols twice and four times daily, respectively, to patients with reversible obstructive lung disease. The study was controlled and double blind, and continued for 12 weeks. Ninety-nine patients from five study centers were included and 89 patients could be properly evaluated. The formoterol-treated patients used significantly less rescue medicine (salbutamol aerosol) and had higher morning PEF values. For the other efficacy variables (daytime FEV1.0, evening PEF, patient and investigator global evaluations, night sleeping time) and tolerance (side effects noted by patients, blood and urine laboratory values, ECG, patient and investigator global evaluation), there were no... (More)
Formoterol, a new beta 2-agonist, and salbutamol were given as aerosols twice and four times daily, respectively, to patients with reversible obstructive lung disease. The study was controlled and double blind, and continued for 12 weeks. Ninety-nine patients from five study centers were included and 89 patients could be properly evaluated. The formoterol-treated patients used significantly less rescue medicine (salbutamol aerosol) and had higher morning PEF values. For the other efficacy variables (daytime FEV1.0, evening PEF, patient and investigator global evaluations, night sleeping time) and tolerance (side effects noted by patients, blood and urine laboratory values, ECG, patient and investigator global evaluation), there were no significant differences between the formoterol- and the salbutamol-treated groups. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Respiration
volume
61
issue
6
pages
305 - 309
publisher
Karger
external identifiers
  • pmid:7824809
  • scopus:0028063491
ISSN
1423-0356
language
English
LU publication?
yes
id
a9428df5-fa93-4509-983f-7f9540562cf7 (old id 1108461)
date added to LUP
2008-07-24 10:55:07
date last changed
2017-01-01 06:51:13
@article{a9428df5-fa93-4509-983f-7f9540562cf7,
  abstract     = {Formoterol, a new beta 2-agonist, and salbutamol were given as aerosols twice and four times daily, respectively, to patients with reversible obstructive lung disease. The study was controlled and double blind, and continued for 12 weeks. Ninety-nine patients from five study centers were included and 89 patients could be properly evaluated. The formoterol-treated patients used significantly less rescue medicine (salbutamol aerosol) and had higher morning PEF values. For the other efficacy variables (daytime FEV1.0, evening PEF, patient and investigator global evaluations, night sleeping time) and tolerance (side effects noted by patients, blood and urine laboratory values, ECG, patient and investigator global evaluation), there were no significant differences between the formoterol- and the salbutamol-treated groups.},
  author       = {Stålenheim, G and Wegener, T and Grettve, L and Lundback, B and Melander, B and Osterman, K and Piitulainen, Eeva and Zetterstrom, O},
  issn         = {1423-0356},
  language     = {eng},
  number       = {6},
  pages        = {305--309},
  publisher    = {Karger},
  series       = {Respiration},
  title        = {Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease},
  volume       = {61},
  year         = {1994},
}